A new formulation of extended-release quetiapine, an atypical antipsychotic medication, should not be approved as a monotherapy for major depressive disorder and generalized anxiety disorder because of serious cardiac and metabolic adverse events associated with use of the drug, according to an advisory panel to the US Food and Drug Administration (FDA). The panel, however, voted in favor of approving more limited use of quetiapine as an adjunctive therapy in treatment-refractory depression.
Kuehn BM. FDA Panel Issues Mixed Decision on Quetiapine in Depression and Anxiety. JAMA. 2009;301(20):2081-2082. doi:10.1001/jama.2009.708